The development of metabolic peptide drugs has followed an interesting progression.
Semaglutide primarily targets one receptor. Tirzepatide targets two. Retatrutide was engineered to activate three.
That makes it tempting to think of these compounds as a simple sequence in which each new molecule adds another receptor and becomes more powerful.
The biology is more complicated than that.
Semaglutide, tirzepatide, and retatrutide have different molecular structures, receptor profiles, pharmacology, clinical-development histories, and levels of regulatory evidence. And while clinical trials have reported progressively larger average weight reductions across some studies, results from separate trials cannot be treated as though the three compounds were randomly compared under identical conditions.
Understanding the differences starts with the receptors themselves.
Three Different Receptor Strategies
The simplest comparison is:
| Compound | Receptor Targets | General Classification |
|---|---|---|
| Semaglutide | GLP-1R | Single receptor agonist |
| Tirzepatide | GIPR + GLP-1R | Dual receptor agonist |
| Retatrutide | GIPR + GLP-1R + GCGR | Triple receptor agonist |
These descriptions refer to functional receptor activity.
They do not mean that the drugs simply contain one, two, or three copies of the same biological signal.
GIP, GLP-1, and glucagon are distinct peptide hormones with different receptors and overlapping but different physiological roles.
Retatrutide therefore represents a more complicated pharmacological strategy than simply adding “more GLP-1.”
Semaglutide: GLP-1 Receptor Agonism
Semaglutide is a GLP-1 receptor agonist.
GLP-1, or glucagon-like peptide-1, is an incretin hormone involved in nutrient-dependent metabolic signaling.
GLP-1 receptor activation can influence:
- glucose-dependent insulin secretion
- glucagon regulation
- appetite and satiety
- gastric function
- energy intake.
The pharmaceutical development of long-acting GLP-1 receptor agonists showed that one peptide receptor pathway could produce substantial metabolic effects when receptor activation was extended over time.
Semaglutide is a modified peptide with structural features that increase albumin binding and prolong exposure compared with endogenous GLP-1.
Its success established GLP-1R as one of the most important metabolic drug targets of the past decade.
Tirzepatide Added the GIP Receptor
Tirzepatide took a different approach.
Rather than activating GLP-1R alone, tirzepatide acts at both:
GIPR
and
GLP-1R.
This is why tirzepatide is usually described as a dual GIP/GLP-1 receptor agonist.
GIP stands for glucose-dependent insulinotropic polypeptide.
Like GLP-1, GIP is an incretin hormone. But the two peptides bind different receptors and produce overlapping rather than identical biology.
The idea behind dual agonism is that simultaneous activity across the two pathways may produce a metabolic response that differs from GLP-1 receptor activation alone.
A direct randomized comparison has now tested that question clinically.
Tirzepatide Has Been Compared Directly With Semaglutide
The SURMOUNT-5 trial randomized 751 adults with obesity but without type 2 diabetes to tirzepatide or semaglutide.
At 72 weeks, average weight change was:
- -20.2% with tirzepatide
- -13.7% with semaglutide
Tirzepatide also produced a larger reduction in waist circumference.
This is much stronger comparative evidence than looking at separate tirzepatide and semaglutide studies.
Why?
Because the two treatments were tested:
- in the same trial
- in a comparable population
- over the same period
- using the same endpoint definitions.
That is what a meaningful head-to-head comparison looks like.
Retatrutide Adds the Glucagon Receptor
Retatrutide goes one receptor further.
It activates:
- GIPR
- GLP-1R
- GCGR.
The glucagon receptor is what makes retatrutide pharmacologically different from tirzepatide.
Retatrutide was originally known by the development code LY3437943.
The discovery work published in Cell Metabolism in 2022 described it as a novel triple glucagon, GIP, and GLP-1 receptor agonist. Researchers found that it had relatively strong GIP receptor activity while maintaining functional activity at GLP-1R and GCGR.
This is often called unimolecular triple agonism.
One peptide molecule carries the entire receptor profile.
Why Add Glucagon Signaling?
Glucagon is commonly associated with raising blood glucose.
That makes its inclusion in a metabolic peptide seem counterintuitive.
But glucagon biology extends beyond glucose production.
Glucagon receptor signaling can also affect:
- hepatic lipid metabolism
- fatty-acid oxidation
- amino-acid metabolism
- nutrient handling
- energy expenditure.
In preclinical retatrutide research, investigators found that GIPR and GLP-1R activity contributed to reduced calorie intake, while GCGR activation added an energy-expenditure component that further increased body-weight reduction in obese mice.
That provides the mechanistic rationale for triple agonism.
But it is important not to overstate the finding.
The contribution of glucagon-mediated energy expenditure has been demonstrated much more clearly in animal experiments than in humans.
Human trials evaluate the complete retatrutide molecule. They do not neatly separate how much of each outcome comes from GIPR, GLP-1R, or GCGR.
Retatrutide Is Not “Semaglutide Plus Tirzepatide”
Multi-receptor agonists are sometimes discussed as though each new compound simply adds another mechanism to the previous drug.
That is not accurate.
Retatrutide and tirzepatide are distinct peptides.
They have different:
- amino-acid sequences
- receptor potencies
- structural modifications
- pharmacokinetics
- dose-response relationships.
Retatrutide was developed as its own molecular system rather than by physically adding glucagon onto tirzepatide.
Two peptides can target overlapping receptors while having very different pharmacological profiles.
Retatrutide Does Not Activate All Three Receptors Equally
The term “triple agonist” can also create the impression of equal activity.
That is not what laboratory assays show.
The original retatrutide research found more functional GIPR activity, with lower potency at the human GLP-1 and glucagon receptors.
That uneven profile may be important.
Modern polyagonist design is not simply about maximizing every receptor.
Researchers are trying to find a useful balance among several pathways.
Too little activity at one receptor may add little.
Too much activity could change glucose control, tolerability, cardiovascular effects, or other physiology.
How the Clinical Weight-Loss Results Compare
Across separate studies, all three compounds have produced substantial average reductions in body weight.
The results most commonly cited include:
- semaglutide: roughly 15% in its pivotal obesity program
- tirzepatide: roughly 21% at higher doses in SURMOUNT-1
- retatrutide: 24.2% at 48 weeks in Phase 2 and up to 28.3% at 80 weeks in TRIUMPH-1.
Retatrutide’s Phase 2 obesity trial enrolled 338 adults without diabetes. At 48 weeks, average weight reduction reached 24.2% in the 12 mg group compared with 2.1% with placebo.
Phase 3 TRIUMPH-1 later reported 28.3% average weight reduction at 80 weeks in the 12 mg group under the efficacy estimand.
Those numbers are notable.
They still do not prove that retatrutide is superior to tirzepatide or semaglutide.
Why Cross-Trial Rankings Are Weak Evidence
Suppose Drug A produces 20% weight reduction in one clinical trial and Drug B produces 25% in another.
It is tempting to conclude that Drug B is 25% more effective.
That conclusion may be wrong.
Trials differ in:
- baseline BMI
- diabetes status
- age
- treatment duration
- dose-escalation schedules
- eligibility criteria
- statistical estimands
- adherence
- discontinuation
- lifestyle interventions.
Even placebo groups can lose different amounts of weight between trials.
So separate trial results are useful for understanding each drug.
They are much less reliable for establishing a ranking.
TRIUMPH-5 Should Give a Better Retatrutide vs. Tirzepatide Answer
That is why TRIUMPH-5 is so important.
The Phase 3 study directly compares retatrutide with tirzepatide in approximately 800 adults with obesity.
Its primary endpoint is percentage change in body weight at week 80.
As of September 2026, TRIUMPH-5 is active but no longer recruiting. Primary completion is estimated for December 2026, and no results have yet been posted.
Until that trial reports, claims that retatrutide is clinically superior to tirzepatide remain ahead of the evidence.
The Safety Profiles Also Need to Be Compared Carefully
Weight reduction is only one part of a treatment’s clinical profile.
All three compounds affect gastrointestinal signaling, and nausea, diarrhea, vomiting, and constipation commonly appear in clinical trials.
In the retatrutide Phase 2 obesity trial, gastrointestinal adverse events were the most common treatment-related issues. They were generally mild to moderate, dose related, and partly reduced by using a lower starting dose.
Retatrutide research has also identified sensory events such as dysesthesia and temporary increases in heart rate.
Its final safety profile is still being established because the molecule remains investigational.
Semaglutide and tirzepatide have a much larger amount of post-approval use and regulatory experience.
That difference in evidence maturity matters as much as the efficacy percentages.
Regulatory Status Is a Major Difference
Semaglutide and tirzepatide have FDA-approved medical uses.
Retatrutide does not.
As of September 2026, retatrutide remains an investigational compound undergoing late-stage development.
Lilly reported positive Phase 3 results from several TRIUMPH studies in 2026 and has said it plans to submit a Biologics License Application to FDA in the first quarter of 2027.
A planned submission is not the same thing as approval.
Regulators still have to evaluate the complete efficacy, safety, manufacturing, and quality data.
Why Retatrutide Is Interesting for Laboratory Research
Retatrutide also has value as a research molecule independent of its eventual regulatory outcome.
Its three-receptor design makes it useful for investigating questions involving:
- GPCR signaling
- polyagonist pharmacology
- receptor potency
- peptide engineering
- metabolic receptor interactions
- analytical characterization
- structure-activity relationships.
Researchers working with a retatrutide research peptide should evaluate the analytical documentation associated with the specific research lot rather than assuming that separately sourced material is identical to Lilly’s clinical-trial formulation.
Research material and investigational pharmaceutical material are different categories.
What the Progression Really Shows
The move from semaglutide to tirzepatide to retatrutide is scientifically interesting because it illustrates a larger change in peptide pharmacology.
The field has moved from asking:
Can we effectively target GLP-1R?
to:
Can we combine complementary receptor pathways within one engineered peptide?
The progression is therefore better thought of as:
single agonism → dual agonism → triple agonism
rather than simply:
older drug → stronger drug → strongest drug.
Each additional receptor adds biological possibilities.
It also adds complexity.
Conclusion
Semaglutide, tirzepatide, and retatrutide represent three different approaches to metabolic peptide pharmacology.
Semaglutide primarily activates GLP-1R.
Tirzepatide combines GIPR and GLP-1R activity.
Retatrutide adds GCGR to create a GIPR/GLP-1R/GCGR triple agonist.
Clinical research suggests that multi-receptor agonism can produce very large metabolic effects. Tirzepatide has already demonstrated superiority to semaglutide for weight reduction in a direct randomized trial.
Retatrutide has produced even larger average reductions in some separate Phase 2 and Phase 3 trials, but there is not yet a completed head-to-head study proving that it is superior to tirzepatide.
TRIUMPH-5 should provide much stronger evidence on that question.
Until then, the most scientifically useful distinction among these molecules is not simply how much weight participants lost.
It is how their receptor architecture differs and what that teaches researchers about single, dual, and triple peptide agonism.
For scientific and laboratory discussion only. Retatrutide remains investigational and is not approved for human or veterinary use.
References
Coskun T, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss. Cell Metabolism. 2022.
Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial. New England Journal of Medicine. 2023.
Aronne LJ, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. New England Journal of Medicine. 2025.
ClinicalTrials.gov. TRIUMPH-5, NCT06662383.